TSLP R Overview
Molecule Name
Thymic stromal lymphopoietin
Synonyms
TSLP R,CRLF2,IL-XR,ILXR,p2RY8,CRLF2 fusion,TSLP receptor,TSLPR,CRL2,CRLF2Y,Cytokine receptor-like 2
Drug Development Progress
Drugs in Clinical Trials28
Approved Drugs1
Highest Development StageApproved
Target Synonym
Thymic stromal lymphopoietin，TSLP
Background
Receptor for thymic stromal lymphopoietin (TSLP). CRLF2 / TSLPR is a member of the type I cytokine receptor family. Together with the interleukin 7 receptor (IL7R) and TSLP activate STAT3, STAT5, and JAK2 pathways, which control processes such as cell proliferation and development of the hematopoietic system.
TSLP R Product List
You Have Viewed 0 Of 0 Results
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| QL-2302 | QL2302; QL-2302 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Asthma | Details |
| GB-0895 | GB-0895 | Phase 3 Clinical | Generate Biomedicines Inc | Asthma; Immune System Diseases; Pulmonary Disease, Chronic Obstructive | Details |
| Tilrekimig | PF-07275315 | Phase 3 Clinical | Pfizer Inc | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| Lunsekimig | SAR-443765 | Phase 3 Clinical | Sanofi | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Inflammation; Pulmonary Disease, Chronic Obstructive | Details |
| Bosakitug | TQC-2731; BSI-045B; TQC2731; ATI-045 | Phase 3 Clinical | Biosion Inc | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis; Dermatitis, Atopic; Eczema; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis | Details |
| SHR-1905 | SHR-1905; AIO-001; GSK-5784283 | Phase 3 Clinical | Jiangsu Hengrui Medicine Co Ltd | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Tract Diseases; Sinusitis | Details |
| CM-326 | CM-326 | Phase 3 Clinical | Keymed Biosciences Co Ltd | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Sinusitis | Details |
| QX-008N | QX-008N; QX008N; JKN-2401; JKN2401; SNCA008; SNCA-008 | Phase 3 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| Solrikitug | NSI-8226; MK-8226 | Phase 2 Clinical | Merck & Co Inc | Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Hypertension; Pulmonary Disease, Chronic Obstructive | Details |
| Ecleralimab | CSJ-117; NOV-14 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| HBM-9378 | HBM-9378; SKB378; SKB-378; A-378; WIN378; WIN-378 | Phase 2 Clinical | Harbour Biomed, Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| CM-512 | CM512; CM-512 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Asthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis | Details |
| IBI-3002 | IBI3002; IBI-3002 | Phase 2 Clinical | Asthma; Dermatitis, Atopic | Details | |
| MG-ZG122 | MG-ZG122; MGZG122 | Phase 2 Clinical | Shanghai Mabgeek Biotechnology Co Ltd | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| AZD-8630 | AZD-8630; AMG-104 | Phase 2 Clinical | Amgen Inc, Astrazeneca Plc | Asthma | Details |
| TAVO-101 | TAVO-101; TAVO101 | Phase 2 Clinical | Tavotek Biotherapeutics (Hong Kong) Ltd | Dermatitis, Atopic; Hypersensitivity | Details |
| PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
| APG273 | APG273; APG-273 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| HBM-7575 | HBM-7575; SKB575; SKB-575; HBM7575 | Phase 1 Clinical | Harbour Biomed | Dermatitis, Atopic; Inflammation | Details |
| WIN-027 | QX027N; QX-027-N; WIN027; WIN-027 | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Dermatitis, Atopic | Details |
| HB-0056 | HB-0056; HB0056 | Phase 1 Clinical | Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive | Details |
| APG-333 | APG333; APG-333; PR018; PR-018 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma | Details |
| SAR-444765 | SAR444765; SAR-444765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| BSI-502 | BSI-502; ATI-052 | Phase 1 Clinical | Biosion Inc | Autoimmune Diseases of the Nervous System; Inflammation | Details |
| CDX-622 | CDX-622 | Phase 1 Clinical | Celldex Therapeutics Inc | Asthma; Fibrosis; Hypersensitivity; Inflammation | Details |
| STSA-1201 | STSA-1201; STSA1201 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Asthma | Details |
| LQ043H | LQ043H | Phase 1 Clinical | Shanghai Novamab Biopharmaceuticals Co Ltd | Asthma | Details |
| GR2002 | GR2002 | Phase 1 Clinical | Genrix (Shanghai) Biopharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Nasal Polyps; Sinusitis | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Tezepelumab | MEDI-9929; AMG-157 | Approved | Amgen Inc | Tezspire | United States | Asthma | Astrazeneca Ab | 2021-12-17 | Anaphylaxis; Asthma; Bronchial Diseases; Carcinoma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Eosinophilic Esophagitis; Granulomatosis with Polyangiitis; Hypersensitivity; Hypersensitivity, Immediate; Immune System Diseases; Lung Diseases; Lung Diseases, Obstructive; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Respiratory Hypersensitivity; Respiratory Tract Diseases; Sinusitis | Details |